Axplora reports that it has invested €35 million ($40.2 million) to expand its Farmabios site in Gropello Cairoli, Italy. This follows a previous €45 million ($52.7 million) investment which brings the total to over €80 million ($93.7 million).
The addition of 62,000 square meters (667,000 square feet) of new development in 2026 will more than double the total footprint of the site to 108,000 square meters (1,162,500 square feet).
According to Mario Di Giacomo, managing director of Farmabios, “We are investing with purpose: to enhance our capabilities, support our partners, and continue leading with innovation and integrity.”
HPAPI processing
This expansion follows a period of accelerated growth at Farmabios over the last five years, he adds, marked by the construction of a new micronization department, expanded warehouse capacity, and the RS40 building, which was unit purpose-built for the “safe and efficient handling of high potent APIs (HPAPIs).”
The facility reportedly supports an Occupational Exposure Limit (OEL) as low as 10 nanograms per cubic meter and complies fully with OEB5 containment criteria. Its design incorporates stand-alone workshops and fully isolated process rooms to mitigate cross-contamination risks, and the micronization rooms are equipped with isolators specifically designed for HPAPI processing.
Axplora officials note that Farmabios is equipped with specialized facilities for cytotoxic and sterile processing, an R&D infrastructure, and a supply chain and warehousing capabilities.
The post Axplora Plans to Expand Its Farmabios Site appeared first on GEN – Genetic Engineering and Biotechnology News.
